ClinicalTrials.gg
CompletedNCT00546819Updated Apr 12, 2017Results posted

ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)

A Phase 2 interventional study of Zoster Vaccine, Live and Comparator: Placebo in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
10th of 29
309 · median 160
Started
2007
with 3 others
Phase 2
5 of 29
none open now
Registered
5th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 10th largest by enrollment, is one of 4 that started in 2007, is one of 5 in phase 2, and was the 5th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

The purpose of the study was to assess the safety, tolerability, and immunogenicity of ZOSTAVAX™ in patients receiving chronic/maintenance corticosteroids.

03

Conditions studied

  • Herpes Zoster

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Varicella-history positive, herpes zoster (HZ)-history negative patients
  • 60 years of age and older receiving chronic/maintenance systemic therapy at a daily dose of 5 to 20 mg of prednisone or equivalent for at least the 2 weeks immediately prior to enrollment and expected to continue to receive a daily dose of 5 to 20 mg of prednisone or equivalent for the 6-week primary safety follow-up period (dose may vary within this range during the 6-week postvaccination period)
  • All females enrolling must be

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of reaction to gelatin or neomycin
  • Prior receipt of varicella or zoster vaccine; prior history of herpes zoster
  • Immune globulin and/or blood products given within 5 months prior to or expected within the 6-week postvaccination period
  • Receipt of any within 1 month or receipt of any inactivated vaccinations within 7 days prior to enrollment
  • Known immune deficiency that is caused by a medical condition
  • Any use in the 8 weeks prior to vaccination or for 6 weeks after vaccination other medications which may suppress the immune system including methotrexate, at a daily dose greater than 20 mg of prednisone or equivalent, agents used to treat cancer, or medications which alter the level of the immune response used to treat arthritis or other illnesses
  • Concomitant use of antiviral therapy
  • A history of alcohol abuse or recreational drug use
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    ZOSTAVAX™

    Participants administered ZOSTAVAX™ on Day 1.

    Biological: Zoster Vaccine, Live

  • Placebo comparator
    Placebo

    Participants administered Placebo on Day 1.

    Biological: Comparator: Placebo

Interventions

  • A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1

    Also known as: V211

  • BiologicalComparator: Placebo

    A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAE)

    A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.

    Time frame: Up to 182 days postvaccination

Secondary outcomes

  1. Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibodies at 42 Days Postvaccination

    The Geometric Mean Titer (GMT) of VZV antibodies in participants' serum samples was assessed by a glycoprotein enzyme-linked immunosorbent assay (gpELISA).

    Time frame: 42 days postvaccination

  2. Geometric Mean Fold Rise (GMFR) of the VZV Antibody Response From Day 1 to Day 42 Postvaccination.

    The geometric mean fold rise (GMFR) of the VZV antibodies from Day 1 to Week 6 postvaccination.

    Time frame: 42 days postvaccination

07

Results

Posted Aug 15, 2011

Participant flow

Participant flow — Overall Study
MilestoneZOSTAVAX™Placebo
Started207102
Vaccinated206100
Completed19996
Not completed86
Withdrew: Adverse event23
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject42

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAE)

A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.

Time frame:
Up to 182 days postvaccination
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAE)
ParticipantsZOSTAVAX™Placebo
Number of Participants With Serious Adverse Events (SAE)2111
SecondaryGeometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibodies at 42 Days Postvaccination

The Geometric Mean Titer (GMT) of VZV antibodies in participants' serum samples was assessed by a glycoprotein enzyme-linked immunosorbent assay (gpELISA).

Time frame:
42 days postvaccination
Reported as:
Mean · gpELISA units/mL
Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibodies at 42 Days Postvaccination
gpELISA units/mLZOSTAVAX™Placebo
Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibodies at 42 Days Postvaccination531.1 (453.3 to 622.1)224.3 (169.8 to 296.2)
SecondaryGeometric Mean Fold Rise (GMFR) of the VZV Antibody Response From Day 1 to Day 42 Postvaccination.

The geometric mean fold rise (GMFR) of the VZV antibodies from Day 1 to Week 6 postvaccination.

Time frame:
42 days postvaccination
Reported as:
Mean · Ratio
Geometric Mean Fold Rise (GMFR) of the VZV Antibody Response From Day 1 to Day 42 Postvaccination.
RatioZOSTAVAX™Placebo
Geometric Mean Fold Rise (GMFR) of the VZV Antibody Response From Day 1 to Day 42 Postvaccination.2.3 (2.0 to 2.7)1.1 (1.0 to 1.2)

Adverse events

Collected over Up to 182 days postvaccination for serious adverse events and 42 days postvaccination for other adverse events.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZOSTAVAX™—21/204 (10.3%)43/204 (21.1%)
Placebo—11/99 (11.1%)10/99 (10.1%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventZOSTAVAX™Placebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders7/2042/99
PneumoniaInfections and infestations3/2042/99
Cardiac arrestCardiac disorders0/2041/99
Hypertensive heart diseaseCardiac disorders0/2041/99
GoitreEndocrine disorders0/2041/99
Large intestine perforationGastrointestinal disorders0/2041/99
Pancreatitis acuteGastrointestinal disorders0/2041/99
Cellulitis of male external genital organInfections and infestations0/2041/99
Gastritis viralInfections and infestations0/2041/99
Scrotal abscessInfections and infestations0/2041/99
Most frequent other events
Most frequent other events
EventZOSTAVAX™Placebo
Injection site erythemaGeneral disorders36/2044/99
Injection site swellingGeneral disorders23/2045/99
Injection site painGeneral disorders22/2048/99

Baseline characteristics

Age, Continuous
Age, Continuous(years)ZOSTAVAX™PlaceboTotal
Mean69.8 ± 6.969.9 ± 7.269.8 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)ZOSTAVAX™PlaceboTotal
Female14080220
Male672289
Daily Corticosteroid Dose Stratum
Daily Corticosteroid Dose Stratum(Participants)ZOSTAVAX™PlaceboTotal
5 to 10 mg of prednisone or equivalent18288270
>10 to 20 mg of prednisone or equivalent251439
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Russell AF, Parrino J, Fisher CL Jr, Spieler W, Stek JE, Coll KE, Su SC, Xu J, Li X, Schlienger K, Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine. 2015 Jun 17;33(27):3129-34. doi: 10.1016/j.vaccine.2015.04.090. Epub 2015 May 8. PubMed 25964168 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2007
First posted
Oct 19, 2007
Start
Oct 2007
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Results first posted
Aug 15, 2011
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00546819
Responsible party
Sponsor
First posted
Oct 19, 2007
Start date
Oct 2007
Primary completion
Aug 2010
Completion
Aug 2010
Results posted
Aug 15, 2011
Last update
Apr 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion